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There is a need for effective nutraceuticals for osteoarthritis care. The fruit of Phyllanthus
emblica is used as a powerful rejuvenator in Ayurvedic medicine. This study measured the
chondroprotective potential of P. emblica (‘Amalaki’) fruits in vitro. We used aqueous extracts
of unprocessed P. emblica fruit powder (powder A), and the powder obtained after hot water
extraction and drying of powder A (powder B). Chondroprotection was measured in three
different assay systems. First, we tested the effects of both fruit powders on the activities of the
enzymes hyaluronidase and collagenase type 2. Second, an in vitro model of cartilage
degradation was set-up with explant cultures of articular knee cartilage from osteoarthritis
patients. Cartilage damage was assayed by measuring glycosaminoglycan release from explants
treated with/without P. emblica fruit powders. Aqueous extracts of both fruit powders
significantly inhibited the activities of hyaluronidase and collagenase type 2 in vitro. Third, in
the explant model of cartilage matrix damage, extracts of glucosamine sulphate and powder B
(0.05mg/ml) exhibited statistically significant, long-term chondroprotective activity in cartilage
explants from 50% of the patients tested. This result is important since glucosamine sulphate is
the leading nutraceutical for osteoarthritis. Powder A induced a statistically significant, short-
term chondroprotective activity in cartilage explants from all of the patients tested. This is the
first study to identify and quantitate new chondroprotective activities of P. emblica fruits. These
data provide pilot pre-clinical evidence for the use of P. emblica fruits as a chondroprotective
agent in osteoarthritis therapy.
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Introduction
Osteoarthritis (OA) is a serious, degenerative disease. A
systematic research of randomized, placebo-controlled
clinical trials performed between 1980 and 2002, con-
firmed the efficacy of oral glucosamine sulphate (GS) on
arthritis (1). However, controversies on therapeutic
efficacy of glucosamine in OA prevail (2–4). Therefore,
it is urgent and important to identify new chondropro-
tective nutraceuticals. Ayurvedic tradition has long
recognized the medicinal properties of Phyllanthus
emblica or Emblica officianlis fruits. Phyllanthus emblica
fruits (‘Amalaki’), are primarily used for their anti-
inflammatory activity and rejuvenating properties.
According to Svoboda, the ancient Indian text
Charakha Samhita; cites ‘Amalaki’ as the single most
potent rejuvenating medicine (5).
Three in vitro assays were used to evaluate the
hypothesis that crude aqueous extracts of P. emblica
For reprints and all correspondence: Venil N. Sumantran, PhD.
Scientist, Interactive Research School for Health Affairs (IRSHA),
Bhartiya Vidyapeeth Deemed University (Medical College Campus),
Dhankawadi, Pune 411043, India. Tel: þ91 2024366929;
Fax:þ91 2024366931; E-mail: venils@hotmail.com irshabv@eth.net
 2007 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.fruit powder exhibit chondroprotective activity. The
matrix-metalloprotease enzymes (MMP’s 1,3,8) express
collagenase type 2 activity which can degrade cartilage
matrix (6). Therefore, in the first assay, we tested effects
of P. emblica fruit powder on the gelatinase activity of
pure collagenase type 2. An earlier report suggested
that P. emblica fruit juice inhibits activity of hyaluro-
nidase (7), an enzyme which degrades cartilage
matrix (8). Thus, in the second assay, we tested effects
of P. emblica fruit powders on the activity of hyalur-
onidase in vitro.
Studies on chondroprotective drugs report that glycos-
aminoglycans (GAG) release by cartilage explants is a
proven marker of cartilage matrix damage in vitro (9,10).
Aggrecan is the major proteoglycan found in cartilage
matrix. Human osteoarthritic explants treated with
glucosamine-3-sulphate showed down regulated expres-
sion of aggrecan and aggrecanase mRNA, suggesting that
glucosamine might reduce enzymatic breakdown of the
extra-cellular matrix (11,12). Therefore in the third assay,
we measured effects of P. emblica fruit powder extracts
on GAG release from explant cultures of cartilage
obtained from chronic OA patients during knee replace-
ment surgery. GS was used as a positive control, to
validate this experimental model.
This is the first report to identify and quantitate three
novel chondroprotective activities of aqueous extracts
of P. emblica fruit powder. First, P. emblica fruit extracts
strongly inhibited activities of hyaluronidase and
collagenase type 2 enzymes in vitro. Next, P emblica
fruit powder B and GS caused a statistically significant,
long-term decrease in levels of glycosaminoglycans
released from human cartilage explants in a subset of
OA patients tested, suggesting that both these drugs
have similar chondroprotective effects on cartilage matrix
in vitro. In contrast, P. emblica fruit powder A showed a
significant short-term chondroprotective effect on carti-
lage explants from all of the patients tested.
Methods
Phyllanthus emblica Fruit Powders
Dried fruits of P. emblica (Indian Goooseberry) were
collected from reliable sources and authenticated at
National Institute of Science Communication and
Information Resources (NISCAIR), New Delhi.
(Standard herbarium specimen Acc. No. 3482).
Standardized, authenticated, P. emblica fruit powders
were obtained from the Department of Health Sciences,
Pune University, as part of the NMITLI-OA project
sponsored by the Council for Scientific and Industrial
Research, New Delhi, India. Powdered fruits were
extracted with hot water. The extract was spray dried
and standardized by HPLC (High Performance Liquid
Chromatography) using gallic acid as a reference
standard. The chromatogram revealed presence of gallic
acid (retention time 4.3min) in the sample at a
wavelength of 270Nm. HPLC Chromatograms can be
provided if required.
We used unprocessed dry fruit powder (powder A), and
the powder obtained after hot water extraction and spray
drying of powder A (powder B). Powders A and B were
solubilized in distilled water (10mg/ml) by limited
autoclaving (5 pounds pressure for 7min); and filter
sterilized (13mm, 0.45mm CN membrane), after addition
to culture media.
Reagents and Tissue Culture Supplies
Growth media, electrophoresis reagents, and collagenase
type 2 were from Life Technologies, Gibco, USA.
Chondroitin sulphate was purchased from Calbiochem
Corp, USA. GS capsules (‘Rejoint’) were from Nicholas
Piramal, Ltd, India. Other reagents were from Qualigens
Corp, India and Sigma Chemicals, (USA). Tissue culture
plasticware was from Falcon Corporation, (USA).
Collagenase Type 2 Enzyme Assay
An electrophoretic assay was used to detect gelatinase
activity of pure collagenase type 2 (13). Enzyme was
freshly prepared (0.50% w/v solution in 50mM Tris
buffer pH 6.8) for each assay.
Hyaluronidase Enzyme Assay
Bovine testicular hyaluronidase (800U/ml) and human
umbilical cord hyaluronic acid (HA) (Potassium salt)
(0.40mg/ml.) were prepared in buffers specified by the
supplier (Calbiochem Corpn, USA). Enzyme activity
was assayed spectrophotometrically by monitoring diges-
tion of HA substrate by the enzyme at 37 C for 1h (14).
Digestion of HA substrate was quantitated by
measuring Absorbance415Nm (A415 Nm). Enzyme activity
ranged from 75–95%, (i.e. enzyme digested 75–95% of
the HA.) This method has been used to screen for
hyaluronidase inhibitors (14). The following formulae
were used for calculations.
(i) A415 Nm value of undigested hyaluronic acid
substrate is set at 100%
(ii) Enzyme activity¼(100%) {A415 Nm of
HAþEnzyme/A415 Nm of HA 100}
(iii) Percent enzyme activity in presence of herbal
extract was calculated using the following ratio:
(ExtractþHAþEnzyme) (Extract alone)/
(ExtractþHA) (Extract alone).
To apply formula number 3, appropriate spectrophoto-
metric data (A415 Nm values) are used for each of the
terms shown within parentheses.
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Patient Profile
Donor cartilage was obtained from OA patients during
knee replacement surgery. Patients of age 55–80 years
had suffered chronic OA for 5–15 years. Only non-
calcified, grade 1–2 cartilage (15) from the lateral femoral
condyles was used.
Explant Cultures
Explant cultures of cartilage from OA patients (10–20mg
each) were set-up within 1.5h of surgery, in 24 well tissue
culture plates. Growth media contained a 1:1 mixture
of DMEM: Ham’s F12 basal media with 10%
heat inactivated fetal bovine serum (FBS)þgentamycin
8mg/ml. After 1day in culture, explants in triplicate,
were treated for 24h with/without sterile aqueous extracts
of powders A or B, (0.05 or 0.10mg/ml). Next, explants
were re-fed with media lacking herbal extract every
2 days for 8 days. Prior to each re-feeding, conditioned
media (CM) samples from explants were collected
and stored at  20 C. Thus, CM samples at four time
points were available from each explant per patient (Day
2,4,6 and 8 days post 24h treatment of explants with/
without herbal extract). Time points of assay labeled as
‘1,2,3,4’ in Figs 2 and 3; correspond to GAG assays done
on CM samples collected on Day 2,4,6 and 8, respec-
tively. Explants were viable for the duration of the
experiment.
DMMB Assay for Glycosaminoglycans
Total GAG content in each CM sample was measured by
the dimethylmethylene blue dye binding assay using
chondroitin sulphate (CS) as a standard (16). Data
is expressed as GAG secreted in microgram equivalents
of CS/mg of explant/ml of CM at each time point
for each patient, in presence/absence of treatment with
drugs.
Data Analysis
Raw data for GAG levels in CM samples released by
explants treated with drugs, were compared with levels of
GAG released by control (untreated) explants from the
same patient at the same time point. Absolute differences
between treated versus control values were tested for
statistical significance using the Students 2 tailed t-test
for paired samples. Data of statistical significance
(P50.05%) were noted.
Presentation of Data
We calculated the effect of drug extracts on GAG present
in each CM sample, at each time point, per patient
sample; using the following ratio: GAG levels in CM
from drug treated Explants/GAG levels in CM from
control Explants. This ratio is graphically expressed as
percent control GAG release for each powder for each
subset of patients. GAG values in drug-treated samples,
which showed a statistically significant decrease from
GAG levels in the corresponding controls (P50.05) are
shown as ‘Responders’. Data which lacked such statis-
tical significance are shown as ‘Non-responders’ (Figs 2
and 3).
Results
Inhibition of Collagenase type 2 by P. Emblica Fruit
Extracts
Figure 1 shows dose dependent inhibition of collagenase
type 2 activity by aqueous extract of P. emblica
fruit powder A. Figure 1 shows that the minimum
inhibitory concentration (MIC) of fruit powder A
required to inhibit the enzyme is 2.5mg/ml (lane 4).
Phyllanthus emblica fruit powder B also gave dose
dependent inhibition of collagenase type 2 activity with
a similar MIC value. As reported, collagenase type 2
was specifically inhibited by the zinc chelator,
o-phenanthroline (17), with an MIC value of 2mm
(data not shown).
Dose dependent Inhibition of Hyaluronidase by P. emblica
Fruit Powders Extracts
Aqueous extracts of P. emblica fruit powders A and B
exhibited dose dependent inhibition of hyaluronidase.
At a concentration of 0.60mg/ml, both powders gave
complete enzyme inhibition in four experiments.
The IC50 value (concentration of powder required to
give 50% enzyme inhibition) was 0.30mg/ml for powders
A and B (Fig. 2). Powder B (0.15mg/ml) gave
19.43 4.08% enzyme inhibition (n¼3). No detec-
table enzyme inhibition was observed with lower con-
centrations (0.03–0.10mg/ml) of either fruit powder.
Figure 1. Inhibition of gelatinase activity of collagenase type 2 by P.
emblica fruit powder A. The gel shows gelatinase activity of collagenase
type 2. The double bands indicate hydrolysis of gelatin on X-ray film by
two forms of the enzyme. Lane 1 shows activity of enzyme alone
(0.50% or 5mg/ml). Lanes 2–6 show activity of the enzyme after
incubation with a final concentration of 10, 5, 2.5, 1.25 and 0.625mg/ml
of extract of P. emblica fruit powder (A), respectively. The minimum
inhibitory concentration (MIC) of fruit powder (A) required to inhibit
the enzyme is 2.5mg/ml (lane 4). This gel is representative of three
experiments.
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that P. emblica fruit juice inhibits hyaluronidase (7).
Effects of P. emblica Fruit Powders in the Explant Model
of OA Cartilage Damage
The inhibition of collagenase type 2 and hyaluronidase
activities by extracts of P. emblica fruit powders, provided
a rationale for testing the effects of these extracts on GAG
release from cartilage explants of OA patients. GS was
used as a positive control in this experimental model.
Long-term Chondroprotective Effects of P. Emblica Fruit
Powder B and Glucosamine
Phyllanthus emblica Fruit Powder B
Figure 3A shows that extracts of P. emblica fruit powder
B (0.05mg/ml) induced a statistically significant long-term
chondroprotective effect in 5/11 OA cases tested. In these
five cases, the levels of PG release in response to fruit
powder B extract were 54.67 12.48%, 64.25 14.27%,
68.57 21.50% and 62.00 26.70% of the control values
in CM samples collected at time points 1,2, 3 and 4,
respectively (P¼0.05 for time points 1,2,3). Thus, treat-
ment with powder B extracts caused a statistically
significant, (45–32%) reduction in GAG release from
explants during the first 3 time points in culture. This
chondroprotective effect of powder B was observed at a
concentration of 0.05mg/ml, but not at 0.10mg/ml (data
not shown).
Figure 3B shows GAG release profiles of cartilage
explants from the six cases which did not give a
chondroprotective response to powder B (non-responders).
In these six cases, GAG release in response to
powder B averaged 107.90 33.30%, 121.12 19.47%,
111.19 22.18%, and 119.64 37.18%, of corresponding
controls at time points 1,2,3 and 4 respectively. These four
GAG values were not significantly different from
corresponding controls at these time points.
Glucosamine Sulphate (GS)
The patient cartilage samples tested with P. emblica fruit
powder B (Fig. 2A), were tested in parallel with GS.
Statistical analysis revealed that GS (0.05mg/ml), caused
a significant reduction in PG release from the explants
for time points 2,3 and 4, in 5/11 patients. Figure 4A
shows that in these five cases, the levels of PG release in
response to GS were 37.04 25.78%, 53.67 13.75%,
(P¼0.05), 54.60 11.29% (P 0.001), and
51.15 13.93% (P 0.001), of the control values from
CM samples collected at time points 1,2,3 and 4,
respectively (P¼0.05). Therefore, treatment with gluco-
samine also caused a significant 47–54% long-term
decrease in GAG release from cartilage explants of
these patients during the culture period.
Figure 4B shows GAG release profiles of cartilage
explants from the six cases which did not respond to GS
(non-responders). In these six cases, levels of GAG
release in response to glucosamine averaged
120.91 12.64%, 118.21 29.81%, 121.67 58.04% and
126.50 34.85% of the corresponding controls at the
time points 1,2,3 and 4, respectively. These four values
were not statistically significantly different from corre-
sponding controls at these 4 time points.
Phyllanthus emblica Fruit Powder A
We then tested effects of aqueous extracts of powder A
on damage of cartilage matrix from OA patients. Use of
powder A allowed testing bioactivity of unprocessed
P. emblica fruits, and verification of the data on powder
B. Due to insufficient cartilage available from each
patient, explants from only 6 of the 11 OA cases were
tested with Powder A. Therefore, cartilage explants from
Inhibition of hyaluronidase by P. emblica fruit
powders A and B
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Figure 2. Hyaluronidase inhibition by P. emblica fruit powders. The
Y axis shows levels of HA measured by the spectrophotometer
(A415Nm) in each sample. The X axis shows the contents of each
sample. Powder A (gray columns): First column shows levels of HA
alone. In presence of enzyme, HA levels decrease by 94% (second
column), showing that hyaluronidase digested 94% of HA substrate.
The third column shows high levels of HA incubated with powder A.
The fourth column shows that addition of hyaluronidase to the mixture
of HAþpowder A, results in a 46% decrease of HA levels; indicative of
decreased enzyme activity. Thus, aqueous extract of fruit powder A
(0.30mg/ml) caused 48% inhibition of enzyme activity (94–46%).
Powder B (black columns): Columns 1 and 2 show that the enzyme
digested 73% of HA substrate. In presence of powder B, enzyme
activity was 18% (columns 3 and 4).Thus, aqueous extract of fruit
powder B (0.30mg/ml) caused 55% inhibition of the enzyme (73–18%).
Each value represents Mean SD of six experiments for powders A and
B. HA¼Hyaluronic acid Enz¼Enzyme (hyaluronidase) A¼P.
emblica fruit powder A B¼P. emblica fruit powder B.
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Figure 3. (A) Responders to powder B in explant model of cartilage damage. Profile of GAG release in five OA cases (cases 1,7,9,10,11) which gave
a long-term chondroprotective response to aqueous extract of powder B (0.05mg/ml) is shown. In these five cases, powder B caused a
significant decrease in the levels of GAG released relative to controls, at time points 1,2,3. Levels of GAG release by controls for all samples is set
at 100%. (B) Non-responders to powder B in explant model of cartilage damage. This graph shows data for 6 of the 11 OA cases (cases 2,3,4,5,6,8)
which did not give a chondroprotective response to aqueous extract of powder B. The levels of GAG release by controls for all samples is
set at 100%.
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Figure 4. (A) Responders to glucosamine in explant model of cartilage damage. The graph shows profile of proteoglycan release in five OA cases
(cases 1,3,8,10,11) which gave a long-term chondroprotective response to glucosamine (0.05mg/ml). In these five cases, glucosamine caused a
statistically significant decrease in the levels of GAG release relative to controls, at time points 2,3 and 4. Levels of GAG release by controls for all
samples is set at 100%. (B) Non-responders to glucosamine in explant model of cartilage damage. This graph shows data for 6 of the 11 OA cases
(cases 2,4,5,6,7,9) which did not give a chondroprotective response to aqueous extract of glucosamine. Levels of GAG release by controls for all
samples is set at 100%.
eCAM 2008;5(3) 333an additional three OA cases were also tested with this
powder (cases 12,13,14); so that cartilage explants from a
total of nine OA patients were tested with powder A
(0.05mg/ml and 0.10mg/ml).
Results showed that explants from nine OA patients
treated with powder A extract (0.10mg/ml), released
65.05 21.27% (P50.005) of GAG levels with respect to
controls, at the first time point only. Therefore, P.
emblica fruit powder A caused a statistically significant
short-term, chondroprotection in explants from all nine
OA patients. In these nine cases, levels of GAG release in
response to powder A, were not significantly different
from controls at subsequent time points (Values of GAG
released in response to powder A were 108.36 29.00%,
108.74 28.60%, and 98.42 32.15% of corresponding
controls at time points 2,3 and 4 respectively). Notably,
lower concentrations of powder A (0.05mg/ml), lacked
chondroprotective activity (data not shown).
Chondroprotective Effects of Glucosamine and P. Emblica
Fruit Powders
Explants from 5/11 OA cases gave a long-term chon-
droprotective response to GS and P. emblica fruit powder
B (Figs 3 and 4), whereas explants from the remaining six
cases gave no significant response to either drug.
Interestingly, three of five cases responded to GS and
Powder B (cases 1,10,11). Similarly, four of six cases did
not respond to either of these drugs (cases 2,4,5,6). Data
showed that Powder A at the higher concentration
(0.10mg/ml) induced a short-term chondroprotective
response in a total of nine cases, (6 of which belong to
the group of 11 cases in which GS and powder B were
tested).
In summary, aqueous extracts of P. emblica fruit
powder B and clucosamine (0.05mg/ml), induce a
comparable long-term chondroprotective response in
cartilage explants from 5/11 OA patients tested. In
contrast, Powder A (0.10mg/ml), induced a short-term
chondroprotective response in cartilage explants from all
nine OA patients in which it was tested
Potencies of Chondroprotective Effects of P. emblica Fruit
Powders A and B
Powder B induced a long-term chondroprotective
response at 0.05mg/ml, whereas powder A induced a
short-term chondroprotective response at 0.10mg/ml.
This data strongly suggests that water extraction of
powder A results in a powder (powder B), with higher
chondroprotective potency. However, powder A was
superior to powder B in terms of the percentage of OA
cartilage samples in which it induced a significant
chondroprotective response. i.e. explants of cartilage of
all nine OA patients tested, responded to powder A
(0.10mg/ml). In contrast, explants from only 5/11 OA
patients, responded to powder B (0.05mg/ml).
Drug Responders versus Non-Responders
One in vitro study also showed that chondrocytes from
40% of OA cases did not show increased aggrecan core
protein levels, and decreased levels of MMP-protein in
response to GS treatment (18). In this context, our data
showing that explants from 5/11 of OA cases were
‘responders’ to the chondroprotective effects
Glucosamine and P. emblica powder B (Figs 3 and 4);
is not surprising. This is because diseased cartilage from
OA patients (during knee replacement) may well give a
partial/heterogenous response to such nutraceuticals.
Indeed, a partial response to glucosamine and
chondroitin sulphate is reported in Glucosamine/
chondroitin Arthritis Intervention Trial (GAIT), the
most comprehensive clinical trial testing the effects of
these nutraceuticals on pain (4). The GAIT study showed
that both nutraceuticals caused a statistically significant
decrease in pain in OA patients with moderate—severe
pain (22% of the patients). However, in patients with
mild pain (78% of the patients), these nutraceuticals did
not cause a significant change in pain levels with respect
to placebo (NCCAM 2006). Therefore, results of the
GAIT study strongly suggest that even the best nutraceu-
ticals only benefit a subset of OA patients. In this context,
our pilot data showing that long-term chondroprotective
activity of P. emblica fruit powder B mimics that of
glucosamine, has pre-clinical value.
The phenomenon of responders and non-responders to
drugs applies to ayurvedic medicine, wherein individual
OA patients would be treated with different drugs
according to body constitution, etc. Our data support
this ayurvedic notion that only a subset of OA cases
respond to P. emblica, because only a subset would have
been prescribed this drug for OA.
Discussion
This is the first report showing chondroprotective activity
of P. emblica fruit powders on human arthritic cartilage
in vitro. Indeed, the long–term chondroprotective activity
of P. emblica fruit powder B is comparable to that of
GS in terms of magnitude and potency (Figs 3 and 4).
Phyllanthus emblica fruit powder A is notable in inducing
a strong short-term chondroprotective response in
cartilage explants from all OA patients in which it was
tested.
These results are physiologically relevant for three
important reasons. First, we only used cartilage from
chronic OA cases, since any chondroprotective drug must
have a therapeutic benefit on arthritic cartilage. Second,
to mimic Ayurvedic formulations, we used crude aqueous
334 Chondroprotective potential of fruit extractsextracts of P. emblica fruit powders. Third, we only used
standard serum containing growth media for cartilage
cultures. For these reasons, the bioactivities of P. emblica
fruit powders measured in this explant model of OA
cartilage damage are likely to reflect their in vivo activity.
Thus far, the cytoprotective actions of P. emblica fruit
in lymphocytes in vitro (19) and in rat models of ischemic
injury (20) have been ascribed to its antioxidant activity.
The mechanisms of chondroprotection by P. emblica fruit
powder B (Fig. 3) and powder A, in human cartilage may
in part be due to its hyaluronidase and gelatinase
inhibitory activities (Figs 1 and 2). In this respect,
polyphenols of blackberry fruit (21) and green tea (22),
reportedly inhibit hyaluronidase and gelatinase activities,
respectively.
None of the commercial chondroprotective drugs are
reported to inhibit hyaluronidase; whereas the drugs
nimusulide (23) and doxycycline (24) inhibit activities of
collagenase and gelatinase in cartilage derived from
osteoarthritis patients in vitro. In this context, the
observed hyaluronidase and gelatinase inhibitory activ-
ities of P. emblica fruit powders is valuable pre-clinical
evidence for an anti-arthritic role for P. emblica fruit.
Future animal and human clinical trials will be required
to extend and confirm these findings.
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